This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by Ohlsen, R. Articles by Barnes, T. PubMed PubMed Citation Articles by Ohlsen, R. Articles by Barnes, T. Social Bookmarking                   What's this?

Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine

MRC SGDP Centre and Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, King's College London, London, UK, r.ohlsen{at}iop.kcl.ac.uk

R. Williamson

MRC SGDP Centre and Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, King's College London, London, UK

B. Yusufi

West London Mental Health Trust, Claybrook Centre, London, UK

J. Mullan

COAST Team (Croydon Early Intervention Psychosis Service), South London and Maudsley NHS Trust, London, UK

D. Irving

Croydon Rehabilitation and Recovery Team, South London and Maudsley NHS Trust, London, UK

S. Mukherjee

West London Mental Health Trust, Claybrook Centre, London, UK

E. Page

Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College London, UK

KJ Aitchison, MRC SGDP

Centre and Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, King's College London, London, UK

TRE Barnes

Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College London, UK

The Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS) was developed to provide a comprehensive measure for rating non-neurological adverse drug reactions (ADRs) to antipsychotics. Although there were already available measures that adequately rated specific non-neurological ADRs, such as sexual side effects, a need was identified for a scale that comprehensively rated the full range of non-neurological ADRs commonly seen across the spectrum of first and second generation antipsychotic drugs, including metabolic and autonomic ADRs. This article reports on work to establish the interrater reliability of an early version and a later, more comprehensive version of the ANNSERS (versions 1 and 2, v1 and v2, respectively). The measures were administered in London centres to patients treated with clozapine. Trained clinicians rated the patients simultaneously and independently. Interrater reliability on the scores was calculated using the kappa coefficient method. The results (mean kappa coefficients of 0.77 and 0.72, respectively) indicate that substantial interrater reliability was achieved for both versions. Items for which the main basis for rating was laboratory investigations rather than patient interview were largely excluded from this study, and kappas were also not calculated for items with a low frequency (less than 10%) of endorsement. Samples of patients on other antipsychotics would be required to reliably calculate kappa coefficients for these items. In conclusion, the ANNSERS represents a clinically applicable research innovation, with good interrater reliability on clinician judged items, which is now available for the comprehensive assessment of non-neurological ADRs to antipsychotics, to aid the processes of clinical audit, research and drug discovery.

Key Words: antipsychotic agent • interrater reliability • adverse drug reaction reporting systems

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?